Compare IART & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | FLGT |
|---|---|---|
| Founded | 1989 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.7M | 867.4M |
| IPO Year | 1995 | 2016 |
| Metric | IART | FLGT |
|---|---|---|
| Price | $11.13 | $26.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $15.00 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 697.1K | 195.6K |
| Earning Date | 02-24-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,642,966,000.00 | $315,549,000.00 |
| Revenue This Year | $3.26 | $16.84 |
| Revenue Next Year | $2.71 | $9.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.99 | ★ 13.61 |
| 52 Week Low | $10.70 | $14.57 |
| 52 Week High | $27.13 | $31.04 |
| Indicator | IART | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 37.37 | 36.98 |
| Support Level | $10.70 | $25.85 |
| Resistance Level | $12.08 | $28.19 |
| Average True Range (ATR) | 0.55 | 0.70 |
| MACD | -0.14 | -0.23 |
| Stochastic Oscillator | 15.72 | 4.19 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.